Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | NEK9 | Q8TD19 | 1/20 | 0.34 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5498749 | 0.99 | KDR (0.37) | KDRPDE3BPDE3APDE10APDPK1 | |
| Hydrochloric Acid SCHEMBL5493969 | 0.87 | KDR (0.44) | KDRPDPK1 | |
| Hydrochloric Acid SCHEMBL7979000 | 0.84 | EGFR (0.45) | KDRPDPK1EGFR | |
| SCHEMBL5274320 | 0.84 | KDR (0.46) | KDRMAPK7ATMENPP1EGFR | |
| Hydrochloric Acid SCHEMBL8187414 | 0.84 | KDR (0.34) | KDRMAPK7ENPP1PDE1B | |
| Hydrochloric Acid SCHEMBL5502661 | 0.83 | KDR (0.45) | KDRMAPK7ATMENPP1EGFR | |
| SCHEMBL5272907 | 0.77 | CHEK1 (0.41) | KDRKDM1AEGFR | |
| SCHEMBL5272824 | 0.77 | KDR (0.46) | KDRPDPK1ATMKDM1ATYK2 | |
| Hydrochloric Acid SCHEMBL5501325 | 0.77 | CHEK1 (0.40) | KDRKDM1AEGFR | |
| SCHEMBL7205793 | 0.73 | KDR (0.48) | KDRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458395-B1 | MEDICAL USE OF GSK3-INHIBITING OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-28 | — | — | EP | claimed |
| US-20050075351-A1 | Use | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | claimed |
| EP-1458395-A1 | NEW USE | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053444-A1 | NEW USE | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | claimed |
| EP-1458395-B1 | MEDICAL USE OF GSK3-INHIBITING OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| US-20050075351-A1 | Use | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458395-A1 | NEW USE | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053444-A1 | NEW USE | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075351-A1 | Use | GSK3A, GSK3B, PYGB | KDR 4361/4885PDE3B 545/4885PDE3A 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.